Medtronic Raises 2027 Forecasts Amid Strong Heart Device Demand
Medtronic enhances its fiscal 2027 projections, fueled by high demand for heart devices and strategic investments in robotics and heart-valve technology.
Medtronic has revised its fiscal 2027 forecasts upward, driven by a surge in demand for its heart devices utilized in complex cardiovascular procedures. The company now anticipates annual organic revenue growth between 7.25% and 7.75%, an increase from its previous estimate of 6.75% to 7.25%. The lower end of its adjusted per share profit forecast has also been raised to $5.94 from $5.90, while the upper end remains at $6.
Strategic Investments and Market Expansion
In a significant move, Medtronic announced an $80 million investment in Pi-Cardia, a maker of heart-valve repair devices, with an option to acquire the company for $210 million. Additionally, the firm has invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select markets outside the United States.
CEO Geoff Martha highlighted the company's strategic focus on high-growth medtech segments, emphasizing the potential of Cornerstone's Sentire robotic system to complement Medtronic's existing Hugo device. Martha noted that the penetration of soft tissue robotic surgery in emerging markets remains below 1%, presenting significant growth opportunities.
Strong Performance in Cardiovascular Segment
Medtronic's cardiovascular segment reported a remarkable 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely attributed to an 88% increase in its pulsed field ablation portfolio, which is designed to address irregular heart rhythms.
Overall, the company posted an adjusted quarterly per share profit of $1.45 on revenues of $9.76 billion, surpassing analysts' expectations of $1.39 per share on $9.55 billion in sales, according to data compiled by LSEG.
Financial Adjustments and Future Outlook
Medtronic's CFO Thierry Pieton remarked on the receipt of tariff refunds that nearly offset the duties paid during the quarter, although these refunds have not been factored into the company's future outlook. The strategic investments and robust demand for heart devices underscore Medtronic's confidence in sustaining growth across its business segments.